				Sh	cet 1 of	
PTO-14	49 REPROI		ATTORNEY DOCKET NO. APPLICATION NO. 0975.1005-018 10/043,436			
*	INFOR	MATION DISCLOSURE STATEMENT, IN AN APPLICATION	FIRST NAMED INVENTOR Junming Le	FILING DATE January 10, 2002		
		(Use several sheets if necessary)	EXAMINER Phillip Gambel	CONFIRMATION NO. GROUP 3843 1644		
·		& TRADEMARY				
	_	U.S. P/	ATENT DOCUMENTS			
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLIC OF CITED DOCUMENT	CANT	
MG-	Al2	US 6,309,640 B1	10/30/2001	Cerami et al.		
M	AJ2	US 6,419 ,9 27 B1	07/16/2002	Cerami et al.		
 	<u> </u>	· · · · · · · · · · · · · · · · · · ·	·			
	ļ					
	<u></u>		· · · · · · · · · · · · · · · · · · ·			
	<u> </u>	· · · · · · · · · · · · · · · · · · ·				
					<u> </u>	
	<u> </u>					
			· · · · · ·		-	
L		·				
					w	
 						
·						
ļ						

EXAMINER PHUPGINDE	DATE CONSIDERED
@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;531725;1	

									Sheet 2 of
PTO-1449 REPRODUCED				ATTORNEY DOCKET NO. APPLICATION N 0975.1005-018 10/043,436			10.		
INFORMATION DISCLOSURE STATESTIC IN AN APPLICATION						filing da January	date ry 10, 2002		
	February 18, 2005 (Use several sheets if necessary) FEB 2 2005			EXAMINER Phillip Gambel		CONFIRMATION NO. 3843		io. groi 164	
		REAL & THE	OF MART		_				
			OREIGN	PATENT DO	DCUMENTS				
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)		DATE DD-YYYY	NAME OF PATENTE OF CITED DO			TRANS YES	LATION NO
p	APT	EP 0 101 681 B1	12/	/14/1994	The Rockefeller U	Jniversity			
	ļ								
	<u> </u>								· · · ·
 							. <u>.</u>		
		· · · · · · · · · · · · · · · · · · ·							
	1			<u> </u>					
		· · · · · · · · · · · · · · · · · · ·							
	ļ								
		·							
				<u></u>	· · · · ·				
	<u> </u>								
	<u> </u>							_	

EXAMINER PHULIP JUBEL	DATE CONSIDERED GROUD
@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;531725;1	

٢

·

•

.6	@PFDesktop\::ODMA/MHC DES/CD/dcm	DDMA/HBSR05;iManage;531726;1 HE UNITED STATES PATH	ENT AND TRADEMA	PATENT APPLICATION DOCKET NO.: 0975.1005-018				
	Applicant:	/ Junming Le, Jan Vilcek, Pete Scott Siegel	r Daddona, John Ghra	John Ghrayeb, David Knight and				
	Application No.:	10/043,436	Group Art Unit:	1644				
	Filed:	January 10, 2002	Examiner:	Phillip Gambel				
	Confirmation No.:	3843						
	Title: METHODS OF TREATING HEPATITIS WITH CHIMERIC ANTI-TNF ANTIBODIES							
		I hereby certify that this corresponden Postal Service with sufficient postage as to Commissioner for Patents, P.O. Box being facsjmile transmitted to the Unite 2-18-05 Date Date Datw	s First Class Mail in an envelope as 1450, Alexandria, VA 22313-14	ed States ddressed 150, or is				

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement is submitted under 37 CFR 1.97(c) together with a \$180.00 fee under 37 CRF 1.17(p).

INFORMATION FROM RELATED LITIGATION

The Rockefeller University and Chiron Corporation have filed a complaint in The United States District Court For The Eastern District of Texas, Marshall Division, Civil Action No. 2-04CV-16, against Centocor, Inc., an assignee of this application, for infringement of U.S. Patent Nos: 6,309,640 and 6,419,927. The accused infringement relates to Centocor, Inc.'s product, REMICADE[®] infliximab. REMICADE[®] infliximab is also known as cA2, which is recited in the claims and specification in this application. The validity of this patent application is not at issue in the litigation. Nor is the validity of any related patents or patent applications at issue in this litigation.

02/24/2005 NBERHE 00000046 10043436

01 FC:1806

180.00°.0P

Enclosed herewith is Form PTO-1449, citing U.S. Patent Nos: 6,309,640 and 6,419,927 and their related European application. Copies of these cited references (AI2, AJ2 and AP7, respectively) are enclosed.

Applicants do not believe that this information is relevant or material to patentability. Applicants merely cite this information in an abundance of caution. Further, Applicants believe that this information is cumulative to References AA and AB, which were cited in the Information Disclosure Statement filed in this application on September 19, 2002. Reference AI2 is a continuation application of Reference AJ2, which is, in turn, a continuation application of References AA and AB and thus have substantially identical disclosures and have the same priority date. In addition, Reference AP7 claims priority to the same priority applications as References AA and AB and has a substantially identical disclosure.

Applicants request that the information disclosed herein be made of record in this application. Applicants respectfully request that the Examiner return a copy of this Supplemental Information Disclosure Statement and acknowledge the information from the related litigation.

6/20/05 PHUR GAMBE

Method of payment:

[X] A check for the fee noted above is enclosed. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Deindre E. Sonters By

Deirdre E. Sanders Registration No.: 42,122 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133 Dated: Fed rharg 18, 2005